COMBI-APlus | CDRB436F2410

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Status

Closed to Accrual

JCP

JCP051

NCT

NCT03551626

CheckMate 238

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

Status

Closed to Accrual

JCP

JCP001

NCT

NCT02388906